Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

NCI sponsors clinical trials with Therion's prostate cancer vaccine

Nov. 22, 1996

First filing for Imutec's Virulizin

Nov. 21, 1996

Final phase II data presented for Biomira's therapeutic cancer vaccine

Nov. 15, 1996

Ovarian cancer vaccine enters pivotal trials in Europe

Nov. 8, 1996

Apoptosis-inducing MAb from Chugai

Nov. 8, 1996

MAb 1DT3-D disclosed for treatment of B-cell lymphoma

Oct. 25, 1996

HER2/neu peptide fragment provokes immune response against tumor cells

Oct. 18, 1996

Ovarian cancer vaccine enters phase II/III trials

Oct. 11, 1996

Patent coverage for The Immune Response Corporation's colon cancer vaccine

Oct. 11, 1996

Chemokine polypeptide from Human Genome Sciences has multiple potential uses

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
GT-02897 exerts efficacy in preclinical multiple myeloma
BioWorld Science
Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...